Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis

Background: Roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI), has been used to treat anemia in patients with chronic kidney disease (CKD). However, its safety and efficacy remain controversial. Methods: The PubMed, EMBASE, Science Citation Index, Cochrane Central Registe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chao, Fu, Zhangning, Jiang, Jiawei, Chi, Kun, Geng, Xiaodong, Mao, Zhi, Song, Chengcheng, Sun, Guannan, Hong, Quan, Cai, Guangyan, Chen, Xiangmei, Sun, Xuefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438137/
https://www.ncbi.nlm.nih.gov/pubmed/34532333
http://dx.doi.org/10.3389/fmed.2021.724456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438137/
https://www.ncbi.nlm.nih.gov/pubmed/34532333
http://dx.doi.org/10.3389/fmed.2021.724456

Ejemplares similares